Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00378976 | HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men. | PHASE3 | COMPLETED | 20 | — | — | Aug 1, 2003 | Jul 1, 2004 | Aug 22, 2013 | 1 | Peru |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| valacyclovir | DRUG | 500 mg twice-daily oral |
| matching placebo | DRUG | twice daily as per experimental drug |
Inclusion Criteria: * Greater than 18 years old, * Documented HIV-1 seropositive, * CD4 count greater than 200, * Not on HIV antiretroviral therapy, * HSV-2 seropositive as determined by Focus EIA (IN \>3.5) * Not intending to move out of the area for the duration of study participation. * Willing ...